BACKGROUND: In those with multiple sclerosis (MS), African American individuals have a more severe disease course, an older age at onset, and more often have clinical manifestations restricted to the optic nerves and spinal cord (opticospinal MS) than white persons. OBJECTIVE: To determine whether genetic variation influences clinical MS patterns. DESIGN: Retrospective multicenter cohort study. PARTICIPANTS: Six hundred seventy-three African American and 717 white patients with MS. MAIN OUTCOME MEASURES: Patients with MS were genotyped for HLA-DRB1 and HLA-DQB1 alleles. The proportion of European ancestry at HLA was estimated by genotyping single-nucleotide polymorphisms with known significant frequency differences in West African and European populations. These genotypes were correlated with the opticospinal disease phenotype, disability measures, and age at onset. RESULTS: Subjects with DRB1*15 alleles were twice as likely to have typical MS rather than opticospinal MS (P = .001). Of the subjects with opticospinal MS or a history of recurrent transverse myelitis who were seropositive for anti-aquaporin 4 antibodies (approximately 5%), none carried DRB1*15 alleles (P = .008). Independently of DRB1*15, African ancestry at HLA correlated with disability as measured by the Multiple Sclerosis Severity Score (P < .001) and risk of cane dependency (hazard ratio, 1.36; P < .001); DRB1*15 alleles were associated with a 2.1-year earlier age at onset (P < .001). CONCLUSIONS: These data indicate that the role of HLA in MS is not limited to disease susceptibility but that genes embedded in this locus also influence clinical outcomes.
BACKGROUND: In those with multiple sclerosis (MS), African American individuals have a more severe disease course, an older age at onset, and more often have clinical manifestations restricted to the optic nerves and spinal cord (opticospinal MS) than white persons. OBJECTIVE: To determine whether genetic variation influences clinical MS patterns. DESIGN: Retrospective multicenter cohort study. PARTICIPANTS: Six hundred seventy-three African American and 717 white patients with MS. MAIN OUTCOME MEASURES: Patients with MS were genotyped for HLA-DRB1 and HLA-DQB1 alleles. The proportion of European ancestry at HLA was estimated by genotyping single-nucleotide polymorphisms with known significant frequency differences in West African and European populations. These genotypes were correlated with the opticospinal disease phenotype, disability measures, and age at onset. RESULTS: Subjects with DRB1*15 alleles were twice as likely to have typical MS rather than opticospinal MS (P = .001). Of the subjects with opticospinal MS or a history of recurrent transverse myelitis who were seropositive for anti-aquaporin 4 antibodies (approximately 5%), none carried DRB1*15 alleles (P = .008). Independently of DRB1*15, African ancestry at HLA correlated with disability as measured by the Multiple Sclerosis Severity Score (P < .001) and risk of cane dependency (hazard ratio, 1.36; P < .001); DRB1*15 alleles were associated with a 2.1-year earlier age at onset (P < .001). CONCLUSIONS: These data indicate that the role of HLA in MS is not limited to disease susceptibility but that genes embedded in this locus also influence clinical outcomes.
Authors: B A C Cree; O Khan; D Bourdette; D S Goodin; J A Cohen; R A Marrie; D Glidden; B Weinstock-Guttman; D Reich; N Patterson; J L Haines; M Pericak-Vance; C DeLoa; J R Oksenberg; S L Hauser Journal: Neurology Date: 2004-12-14 Impact factor: 9.910
Authors: D Brassat; C Azais-Vuillemin; J Yaouanq; G Semana; J Reboul; I Cournu; C Mertens; G Edan; O Lyon-Caen; M Clanet; B Fontaine Journal: Neurology Date: 1999-05-12 Impact factor: 9.910
Authors: R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: Nick Patterson; Neil Hattangadi; Barton Lane; Kirk E Lohmueller; David A Hafler; Jorge R Oksenberg; Stephen L Hauser; Michael W Smith; Stephen J O'Brien; David Altshuler; Mark J Daly; David Reich Journal: Am J Hum Genet Date: 2004-04-14 Impact factor: 11.025
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Noriko Isobe; Lohith Madireddy; Pouya Khankhanian; Takuya Matsushita; Stacy J Caillier; Jayaji M Moré; Pierre-Antoine Gourraud; Jacob L McCauley; Ashley H Beecham; Laura Piccio; Joseph Herbert; Omar Khan; Jeffrey Cohen; Lael Stone; Adam Santaniello; Bruce A C Cree; Suna Onengut-Gumuscu; Stephen S Rich; Stephen L Hauser; Stephen Sawcer; Jorge R Oksenberg Journal: Brain Date: 2015-03-28 Impact factor: 13.501
Authors: Riley Bove; Tanuja Chitnis; Bruce Ac Cree; Mar Tintoré; Yvonne Naegelin; Bernard Mj Uitdehaag; Ludwig Kappos; Samia J Khoury; Xavier Montalban; Stephen L Hauser; Howard L Weiner Journal: Mult Scler Date: 2017-08-29 Impact factor: 6.312
Authors: Noriko Isobe; Pierre-Antoine Gourraud; Hanne F Harbo; Stacy J Caillier; Adam Santaniello; Pouya Khankhanian; Martin Maiers; Stephen Spellman; Nezih Cereb; SooYoung Yang; Marcelo J Pando; Laura Piccio; Anne H Cross; Philip L De Jager; Bruce A C Cree; Stephen L Hauser; Jorge R Oksenberg Journal: Neurology Date: 2013-06-14 Impact factor: 9.910
Authors: B A Johnson; J Wang; E M Taylor; S J Caillier; J Herbert; O A Khan; A H Cross; P L De Jager; P-A F Gourraud; B C A Cree; S L Hauser; J R Oksenberg Journal: Genes Immun Date: 2009-10-29 Impact factor: 2.676